Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

T1D-CATCH Protocol: Collaboration Around Technology Using Community Health Workers for Young Adults With Type 1 Diabetes (T1D-CATCH)

20 oktober 2026 bijgewerkt door: Albert Einstein College of Medicine

The objective of this study is to test the early effects and implementation of an enhanced community health worker (CHW) model (T1D-CATCH) that encourages and supports diabetes technology use in young adults from underrepresented minority groups (YA-URMs) with type 1 diabetes (T1D). The investigators will conduct a 9-month randomized controlled trial in which YA-URMs will be randomized to T1D-CATCH or usual care. The investigators will recruit from adult and pediatric endocrinology and primary care practices in a large safety-net health system in the Bronx, New York. Our specific aims are to 1) evaluate T1D-CATCH effects on technology initiation and continued use over 6 months and 2) evaluate T1D-CATCH implementation using Proctor's Taxonomy of Implementation Outcomes: feasibility, adoption, fidelity, and cost.

Studie Overzicht

Toestand

Voltooid

Interventie / Behandeling

Gedetailleerde beschrijving

The study will involve a 9-month randomized control trial of usual care versus T1D-CATCH, an intervention that enhances core community health worker (CHW) service roles to support increased use of T1D technology in young adults (underrepresented minorities) (YA-URM's). Participants will be recruited from primary and specialty care practices at Montefiore Medical Center in the Bronx, New York, which is a large safety-net hospital system in one of the poorest counties in the U.S. Two young adult-aged CHWs from the Montefiore CHW program will be trained extensively per our Supporting Emerging Adults with Diabetes (SEAD) program manuals. For YA-URMs, CHWs will conduct hands-on diabetes technology education, goal-setting, peer support, and social service linkage. CHWs will also help shift insurance approval tasks away from busy providers and better align patient-provider priorities through close communication between the YA-URM and provider. Group sessions will be optional and will follow the YA-centric education curriculum developed in Dr. Agarwal's Supporting Emerging Adults with Diabetes (SEAD) program.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

119

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • New York
      • The Bronx, New York, Verenigde Staten, 10461
        • Albert Einstein College of Medicine

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 35 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • T1D duration ≥6 months
  • 18-35 years old
  • Self-identified URM status: non-Hispanic Black or Hispanic
  • English- or Spanish-speaking
  • Not currently on a connected diabetes technology system (includes never offered, prescribed but not started within 3 months of receiving the device, discontinued, or previously refused technology)

Exclusion Criteria:

  • Developmental or sensory disability interfering with study participation
  • Current pregnancy
  • Participation in another behavioral or diabetes technology intervention study in the past 6 months.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Onderzoek naar gezondheidsdiensten
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: T1D-CATCH

The CHW intervention will consist of both individual and optional group sessions with YA-URMs with T1D. In individual sessions, CHWs will provide T1D technology education, peer support, and social needs management. Over the 9-month study period, session frequency will involve weekly individual sessions based on participant technology milestones and an optional monthly CHW-led peer group support session. CHW individual and group sessions will be held via videoconferencing or in person, per participant preference and institutional COVID-19 rules.

As defined by the Centers for Disease Control and Prevention (CDC), a CHW is "a frontline public health worker who is a trusted member of a community or who has a thorough understanding of the community being served, and leverages this unique position to link health systems, social services, and communities". CHWs engender trust with patients by having direct community and lived experience, offering specific support and empathy that may be difficult for other diabetes care professionals to provide. In addition, CHWs have firsthand understanding of cultural barriers to traditional western healthcare and can promote patient-centered culturally-relevant care. They enhance team-based care by helping providers with extra outreach, social needs management, time-consuming tasks, and aligning patient-provider priorities.

CHWs in this project will provide social needs assessment and management, introduction to diabetes technologies, and support for onboarding to technology.

Geen tussenkomst: Usual Care Control Condition

Control arm participants will receive usual primary or endocrine care at Montefiore. Usual care consists of a physician or nurse practitioner visit with review of blood sugars and treatment decisions based on provider experience. Physicians in endocrinology practices are nested within a diabetes center with access to diabetes nurse practitioners/educators, dieticians, a psychologist, and nurses. In all practices, patients are recommended to see their physician or nurse practitioner every 3 months and attend individual or group sessions.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Technology Initiation
Tijdsspanne: Up to 6 months after initiating intervention

Technology initiation will be assessed by the percentage of participants initiating diabetes technology and will be reported as a binary variable (yes/no). Technology will include any combination of continuous glucose monitor (CGM), insulin pump, or CGM and insulin pump. Technology initiation will be defined as at least 1 week of first use during the 6-month period following intervention. Data will be ascertained from electronic medical record (EMR) prescriptions, participant self-reporting, CHW dashboard, and device platform data. Variables will be summarized by study group using summary statistics with counts/percentages.

Up to 6 months after initiating intervention

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Technology Initiation
Tijdsspanne: Up to 3 months after initiating intervention

Technology initiation will be assessed by the percentage of participants initiating diabetes technology and will be reported as a binary variable (yes/no). Technology will include any combination of continuous glucose monitor (CGM), insulin pump, or CGM and insulin pump. Technology initiation will be defined as at least 1 week of first use during the 3-month period following intervention. Data will be ascertained from electronic medical record (EMR) prescriptions, participant self-reporting, CHW dashboard, and device platform data. Variables will be summarized by study group using summary statistics with counts/percentages.

Up to 3 months after initiating intervention
Continued Technology Use - Percent Use
Tijdsspanne: 9 months following intervention

Continued technology use by study end will be determined from device platform metrics detailing days/percent time used, in addition to self-report. Per standard diabetes technology clinical trial guidelines, CGM use is defined as pump use >90% time. The percentage of time used (% used) will be summarized by study arm using basic descriptive statistics. A target of at least 90% CGM wear-time is associated with the best outcomes for glycemic control.

9 months following intervention
Continued Technology Use - Days of Wear
Tijdsspanne: 9 months following intervention

Continued technology use by study end will be determined from device platform metrics detailing days/percent time used, in addition to self-report. Per standard diabetes technology clinical trial guidelines, CGM use is defined as ≥ 5/7 days wear over the 9 month period. Days of wear will be summarized study arm using basic descriptive statistics. A target of at least 5/7 days of CGM wear-time is associated with the best outcomes for glycemic control.

9 months following intervention

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Feasibility Check
Tijdsspanne: 6 months (post-intervention)

Post-intervention interviews examining intervention content, complexity, comfort, delivery, and credibility

6 months (post-intervention)
Adoption
Tijdsspanne: 9 months (post-intervention)

Measured by recruitment logs

9 months (post-intervention)
Adoption
Tijdsspanne: 9 months (post-intervention)

Measured by electronic medical records (EMR)

9 months (post-intervention)
Adoption
Tijdsspanne: 9 months (post-intervention)

Measured by young adult participant consent rates

9 months (post-intervention)
Adoption
Tijdsspanne: 9 months (post-intervention)

Measured by percentage of provider opt-in

9 months (post-intervention)
Adoption
Tijdsspanne: 9 months (post-intervention)

Measured by CHW communications

9 months (post-intervention)
Fidelity
Tijdsspanne: Baseline

Measured by the community health worker (CHW) dashboard

Baseline
Fidelity
Tijdsspanne: Baseline

Measured by electronic medical records (EMR) to analyze session attendance

Baseline
Fidelity
Tijdsspanne: Baseline

Measured by content delivery

Baseline
Fidelity
Tijdsspanne: 3 month mark

Measured by community health workers (CHW) dashboard

3 month mark
Fidelity
Tijdsspanne: 3 month mark

Measured by CHW session recordings

3 month mark
Fidelity
Tijdsspanne: 3 month mark

Measured by EMR to analyze session attendance

3 month mark
Fidelity
Tijdsspanne: 3 month mark

Measured by content delivery

3 month mark
Fidelity
Tijdsspanne: 3 month mark

Measured by insurance tasks

3 month mark
Fidelity
Tijdsspanne: 6 month mark

Measured by CHW dashboard

6 month mark
Fidelity
Tijdsspanne: 6 month mark

Measured by CHW session recordings

6 month mark
Fidelity
Tijdsspanne: 6 month mark

Measured by EMR to analyze session attendance

6 month mark
Fidelity
Tijdsspanne: 6 month mark

Measured by content delivery

6 month mark
Fidelity
Tijdsspanne: 6 month mark

Measured by insurance tasks

6 month mark
Cost
Tijdsspanne: 6 months (post-intervention)

Measured by time sheets, receipts, and budget to analyze CHW salary/benefits

6 months (post-intervention)
Cost
Tijdsspanne: 6 months (post-intervention)

Measured by time sheets, receipts, and budget to analyze CHW equipment

6 months (post-intervention)
Cost
Tijdsspanne: 6 months (post-intervention)

Measured by time sheets, receipts, and budget to analyze CHW consumables

6 months (post-intervention)
YA-URM Autonomy/ Competence, Social Support
Tijdsspanne: Baseline

Measured using the Healthcare Self-Determination survey

Baseline
YA-URM Autonomy/ Competence, Social Support
Tijdsspanne: 3 month mark

Measured using the Healthcare Self-Determination survey

3 month mark
YA-URM Autonomy/ Competence, Social Support
Tijdsspanne: 6 month mark

Measured using the Healthcare Self-Determination survey

6 month mark
YA-URM Autonomy/ Competence, Social Support
Tijdsspanne: 9 month mark

Measured using the Healthcare Self-Determination survey

9 month mark
Hemoglobin A1c
Tijdsspanne: Baseline

Obtained by POC (in clinic) or laboratory (DCA Vantage)

Baseline
Hemoglobin A1c
Tijdsspanne: 3 month mark

Obtained by POC (in clinic) or laboratory (DCA Vantage)

3 month mark
Hemoglobin A1c
Tijdsspanne: 6 month mark

Obtained by POC (in clinic) or laboratory (DCA Vantage)

6 month mark
Hemoglobin A1c
Tijdsspanne: 9 month mark

Obtained by POC (in clinic) or laboratory (DCA Vantage)

9 month mark
Quality of Life (Diabetes Distress)
Tijdsspanne: Baseline

Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA)

Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

Baseline
Quality of Life (Diabetes Distress)
Tijdsspanne: Baseline

Validated surveys: Problem Areas in Diabetes (PAID)

The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100.

  • Total scores of 40 and above: severe diabetes distress
  • Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
Baseline
Quality of Life (Diabetes Distress)
Tijdsspanne: Baseline

Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

Baseline
Quality of Life (Diabetes Distress)
Tijdsspanne: Baseline

Validated survey: Healthcare Climate Questionnaire (HCCQ)

Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree

Higher average scores represent a higher level of perceived autonomy support.

Baseline
Quality of Life (Diabetes Distress)
Tijdsspanne: 3 month follow-up

Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA)

Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

3 month follow-up
Quality of Life (Diabetes Distress)
Tijdsspanne: 3 month follow-up

Validated surveys: Problem Areas in Diabetes (PAID)

The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100.

  • Total scores of 40 and above: severe diabetes distress
  • Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
3 month follow-up
Quality of Life (Diabetes Distress)
Tijdsspanne: 3 month follow-up

Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

3 month follow-up
Quality of Life (Diabetes Distress)
Tijdsspanne: 3 month follow-up

Validated survey: Healthcare Climate Questionnaire (HCCQ)

Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree

Higher average scores represent a higher level of perceived autonomy support.

3 month follow-up
Quality of Life (Diabetes Distress
Tijdsspanne: 6 month follow-up

Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA)

Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

6 month follow-up
Quality of Life (Diabetes Distress)
Tijdsspanne: 6 month follow-up

Validated surveys: Problem Areas in Diabetes (PAID)

The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100.

  • Total scores of 40 and above: severe diabetes distress
  • Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
6 month follow-up
Quality of Life (Diabetes Distress)
Tijdsspanne: 6 month follow-up

Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

6 month follow-up
Quality of Life (Diabetes Distress)
Tijdsspanne: 6 month follow-up

Validated survey: Healthcare Climate Questionnaire (HCCQ)

Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree

Higher average scores represent a higher level of perceived autonomy support.

6 month follow-up

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Shivani Agarwal, MD, MPH, Albert Einstein College of Medicine

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

7 november 2022

Primaire voltooiing (Werkelijk)

8 september 2025

Studie voltooiing (Werkelijk)

8 december 2025

Studieregistratiedata

Eerst ingediend

16 december 2021

Eerst ingediend dat voldeed aan de QC-criteria

26 januari 2022

Eerst geplaatst (Werkelijk)

27 januari 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 november 2026

Laatste update ingediend die voldeed aan QC-criteria

20 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 2021-13714
  • R01DK132302 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren